Ipilimumab in the treatment of metastatic melanoma: management of adverse events

Recently, "ipilimumab," an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. "CTLA-4" is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targ...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2014-01, Vol.7, p.203-209
Main Authors: Della Vittoria Scarpati, Giuseppina, Fusciello, Celeste, Perri, Francesco, Sabbatino, Francesco, Ferrone, Soldano, Carlomagno, Chiara, Pepe, Stefano
Format: Article
Language:English
Subjects:
adverse events
autoimmunity
Cancer
CTLA-4
Drug therapy
Ipilimumab
Melanoma
Oncology, Experimental
Patient outcomes
Review
T-cells
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, "ipilimumab," an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. "CTLA-4" is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targeting CTLA-4, is able to remove the CTLA-4 inhibitory signal, allowing the immune system to react to cancer cells. Due to its immune-based mechanism of action, ipilimumab causes the inhibition of CTLA-4-mediated immunomodulatory effects, the enhancement of antitumor specific immune response mediated by the weakening of self-tolerance mechanisms while exacerbating the development of autoimmune diseases and immune-related adverse events, including dermatitis, hepatitis, enterocolitis, hypophysitis, and uveitis.
ISSN:1178-6930
1178-6930
DOI:10.2147/ott.s57335